MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
69.11
-0.86
-1.23%
Pre Market: 71.05 +1.94 +2.81% 05:30 03/27 EDT
OPEN
69.29
PREV CLOSE
69.97
HIGH
74.83
LOW
67.64
VOLUME
38
TURNOVER
517.71K
52 WEEK HIGH
240.00
52 WEEK LOW
4.275
MARKET CAP
94.82M
P/E (TTM)
-1.3596
1D
5D
1M
3M
1Y
5Y
1D
Wednesday Sector Leaders: Biotechnology, Precious Metals
NASDAQ · 1d ago
Weekly Report: what happened at SPRB last week (0316-0320)?
Weekly Report · 4d ago
Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline
TipRanks · 6d ago
Spruce Biosciences Says On March 16, Entered Termination Agreement With Kaken Pharmaceutical; Collaboration Agreement With Kaken Pharmaceutical To Terminate Effective March 31, 2026; All Licenses & Rights Granted By Co To Kaken To Be Terminated; No Unearned Milestone Payments Or Royalties
Benzinga · 6d ago
SPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILING
Reuters · 6d ago
SPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIES
Reuters · 6d ago
Spruce Biosciences FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million
Reuters · 6d ago
Weekly Report: what happened at SPRB last week (0309-0313)?
Weekly Report · 03/16 09:30
More
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

Webull offers Spruce Biosciences, Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.